Do patients have influence on drug development?
Almost one-third (32%) of bio pharma executives think patients will be very or extremely influential in the success or failure of new drug therapies over the next five years. In stark contrast, only 11% of patients feel they will be influential in which new prescription drugs are available over that same time period. • What should biopharma do to accelerate products to market? Among bio pharma executives, 73% report that they are currently working with partners to share financial risk and best practices. Managed care executives agree with this approach and add that pharma also should use data and decision models in new ways (79%). “A reality of the New Health is that payers and patients are looking to bio pharma to drive innovation and to transform the drug development model,” Norman said. “One of the first steps is for bio pharma to work to close the gap in the perception of value. Bio pharma also must explore alternative alliances that leverage the capabilities of each partner to inc
